Form 4: Axogen Officer's Equity Changes: Vesting & Tax Withholding

Axogen's Chief Innovation Officer, Erick DeVinney, reported the vesting of performance-based shares and restricted stock units, alongside tax-related share withholdings.

Summary

• Erick DeVinney, Chief Innovation Officer of Axogen, Inc., reported changes in his beneficial ownership of company stock.
• On February 26, 2026, 33,780 shares of common stock vested due to the attainment and certification of specific performance criteria.
• On the same date, 10,702 shares of common stock were withheld by Axogen at a price of $31.9 per share to cover tax liabilities incurred from the vesting of performance stock units (PSUs).
• On March 1, 2026, an additional 11,276 shares of common stock were withheld by Axogen at a price of $30.65 per share to cover tax liabilities from the vesting of restricted stock units (RSUs).
• No shares were sold by Mr. DeVinney in these tax-related transactions.
• Mr. DeVinney also acquired 23,000 Restricted Stock Units (RSUs) on February 26, 2026, each representing a contingent right to receive one share of Axogen, Inc. common stock.
• These 23,000 RSUs will fully vest on February 26, 2030, with 50% vesting on February 26, 2028, and an additional 25% vesting each subsequent 12 months.
• Following these transactions, Mr. DeVinney directly beneficially owns 252,934 shares of common stock and 23,000 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. The vesting of performance shares indicates the achievement of company goals, and the new RSU grant reinforces long-term executive alignment, despite the routine tax-related share withholdings.

Positives

• The vesting of 33,780 shares of common stock indicates the attainment and certification of certain performance criteria by the Chief Innovation Officer, suggesting positive operational or strategic achievements.
• The grant of 23,000 Restricted Stock Units aligns the Chief Innovation Officer's long-term incentives with shareholder value.

Negatives

• The disposition of 21,978 shares (10,702 + 11,276) for tax withholding, while not a sale by the officer, reduces the officer's direct beneficial ownership of common stock.

Future Outlook

The filing indicates a long-term incentive structure for the Chief Innovation Officer, with Restricted Stock Units vesting over a four-year period until February 2030, aligning executive compensation with future company performance.

Industry Context

StockSavvy.ai notes that equity compensation, including performance stock units and restricted stock units, is a standard practice in the biotechnology and medical device industries, such as Axogen's, to attract, retain, and incentivize key executives. The vesting of performance-based awards suggests the company is meeting internal targets, which is a positive signal for operational execution within the sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of performance-based equity awards and multi-year vesting schedules for RSUs is consistent with compensation practices seen in comparable medical technology companies. For instance, companies like Stryker (SYK) and Medtronic (MDT) frequently utilize similar long-term incentive plans to align executive interests with shareholder value over extended periods.
• The specific vesting criteria for performance shares are not detailed, but the fact of vesting suggests achievement of pre-defined goals, a common benchmark for executive performance in the industry.

Stakeholder Impact

• Shareholders: The vesting of performance shares suggests the company is meeting its internal targets, which could be viewed positively. The long-term RSU vesting aligns executive incentives with shareholder value. The slight reduction in direct beneficial ownership due to tax withholding is a routine event.
• Employees: The compensation structure for a key officer may reflect broader compensation philosophies within the company.

Next Steps

• Delivery of vested shares to the reporting person upon their respective vesting dates.
• Continued vesting of the 23,000 Restricted Stock Units according to the schedule: 50% on February 26, 2028, and 25% each 12 months thereafter until fully vested on February 26, 2030.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation events for a key executive, including the vesting of performance-based awards and new RSU grants, alongside standard tax withholdings. While the vesting of performance shares is a positive indicator of goal achievement, these are expected occurrences and do not present new information that would fundamentally alter the investment thesis for Axogen. Therefore, a 'hold' recommendation is appropriate as the filing does not provide a strong catalyst for either buying or selling the stock.

Keywords

Axogen, AXGN, SEC Form 4, Insider Trading, Beneficial Ownership, Stock Vesting, Restricted Stock Units, Performance Stock Units, Erick DeVinney, Chief Innovation Officer, Equity Compensation, Tax Withholding